These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17627490)

  • 21. Use of aripiprazole for psychosis and agitation in dementia.
    Laks J; Miotto R; Marinho V; Engelhardt E
    Int Psychogeriatr; 2006 Jun; 18(2):335-40. PubMed ID: 16255839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of the agitation of late-life psychosis and Alzheimer's disease.
    Salzman C
    Eur Psychiatry; 2001 Jan; 16 Suppl 1():25s-28s. PubMed ID: 11520475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of quality of life in Alzheimer's disease: perspective of patients, informal caregivers, and professional caregivers.
    Gómez-Gallego M; Gómez-Amor J; Gómez-García J
    Int Psychogeriatr; 2012 Nov; 24(11):1805-15. PubMed ID: 22697366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.
    Mintzer JE; Tune LE; Breder CD; Swanink R; Marcus RN; McQuade RD; Forbes A
    Am J Geriatr Psychiatry; 2007 Nov; 15(11):918-31. PubMed ID: 17974864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New hope for Alzheimer's dementia as prospects for disease modification fade: symptomatic treatments for agitation and psychosis.
    Stahl SM
    CNS Spectr; 2018 Oct; 23(5):291-297. PubMed ID: 30382934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical antipsychotic medications in Alzheimer's disease: effectiveness versus expectations.
    Schultz SK
    Am J Psychiatry; 2008 Jul; 165(7):787-9. PubMed ID: 18593779
    [No Abstract]   [Full Text] [Related]  

  • 27. Early Improvements of Individual Symptoms With Antipsychotics Predict Subsequent Treatment Response of Neuropsychiatric Symptoms in Alzheimer's Disease: A Re-Analysis of the CATIE-AD Study.
    Nagata T; Shinagawa S; Yoshida K; Noda Y; Shigeta M; Mimura M; Nakajima S
    J Clin Psychiatry; 2020 Feb; 81(2):. PubMed ID: 32074412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options.
    Lesser JM; Hughes S
    Geriatrics; 2006 Dec; 61(12):14-20. PubMed ID: 17184138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic treatment of psychosis and agitation in the elderly.
    Daniel DG
    J Clin Psychiatry; 2000; 61 Suppl 14():49-52. PubMed ID: 11154017
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consequences of antipsychotic medications for the dementia patient.
    Devanand DP; Schultz SK
    Am J Psychiatry; 2011 Aug; 168(8):767-9. PubMed ID: 21813491
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of antipsychotics in dementia depended on the definition of patients and outcomes: a meta-epidemiological study.
    Smeets CHW; Zuidema SU; Hulshof TA; Smalbrugge M; Gerritsen DL; Koopmans RTCM; Luijendijk HJ
    J Clin Epidemiol; 2018 Sep; 101():17-27. PubMed ID: 29782995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease.
    Lopez OL; Wisniewski SR; Becker JT; Boller F; DeKosky ST
    Arch Neurol; 1999 Oct; 56(10):1266-72. PubMed ID: 10520944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
    Gleason RP; Schneider LS
    J Clin Psychiatry; 1990 Mar; 51(3):115-8. PubMed ID: 1968457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discontinuation of risperidone in Alzheimer's disease.
    Ling SM; Bonner AF; McMullen TL
    N Engl J Med; 2013 Jan; 368(2):187. PubMed ID: 23301740
    [No Abstract]   [Full Text] [Related]  

  • 35. Discontinuation of risperidone in Alzheimer's disease.
    Power GA
    N Engl J Med; 2013 Jan; 368(2):186-7. PubMed ID: 23301739
    [No Abstract]   [Full Text] [Related]  

  • 36. Discontinuation of risperidone in Alzheimer's disease.
    Gnjidic D; Hilmer SN
    N Engl J Med; 2013 Jan; 368(2):186. PubMed ID: 23301738
    [No Abstract]   [Full Text] [Related]  

  • 37. Discontinuation of risperidone in Alzheimer's disease.
    Devanand DP; Schultz SK; Sultzer DL
    N Engl J Med; 2013 Jan; 368(2):187-8. PubMed ID: 23301737
    [No Abstract]   [Full Text] [Related]  

  • 38. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lithium Treatment for Agitation in Alzheimer's disease (Lit-AD): Clinical rationale and study design.
    Devanand DP; Strickler JG; Huey ED; Crocco E; Forester BP; Husain MM; Vahia IV; Andrews H; Wall MM; Pelton GH
    Contemp Clin Trials; 2018 Aug; 71():33-39. PubMed ID: 29859917
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Citalopram for agitation in Alzheimer's disease: design and methods.
    Drye LT; Ismail Z; Porsteinsson AP; Rosenberg PB; Weintraub D; Marano C; Pelton G; Frangakis C; Rabins PV; Munro CA; Meinert CL; Devanand DP; Yesavage J; Mintzer JE; Schneider LS; Pollock BG; Lyketsos CG;
    Alzheimers Dement; 2012; 8(2):121-30. PubMed ID: 22301195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.